Physician Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Abbott
U.S. FDA approval granted for once-daily Kaletra (lopinavir/ritonavir)
June 22nd, 2005
Abbott announced that it received U.S. Food and Drug Administration (FDA) approval to market a once-daily dosing regimen for Kaletra (lopinavir/ritonavir), a protease inhibitor used in combination with other anti-HIV medications, for the initial treatment of HIV. The new dosing regimen for Kaletra offers physicians and patients increased flexibility in managing their individual HIV treatment without sacrificing the proven efficacy of the twice-daily dosing option, in patients new to HIV therapy. This new dosing option is available in both liquid and soft gel capsule formulations. "We are pleased to be able to provide patients with a once-daily,...
Source: Physician Law Weekly (2005-06-22)
|
